#USA #Atlanta #Women's Health #PCOS Challenge #PMOS

PCOS Challenge's Response to the Global Renaming of PCOS

On May 12, 2026, the PCOS Challenge, the leading organization advocating for individuals affected by polycystic ovary syndrome (PCOS), issued an important statement regarding the global decision to rename the condition as polyendocrine metabolic ovarian syndrome (PMOS). This change, while provoked by a desire for better diagnosis and treatment options, has raised significant ethical and practical concerns.

The Reason Behind the Renaming

For years, PCOS has been a topic of debate in the medical community, with many professionals recognizing that the term does not encompass the complex nature of the disorder. The harms associated with the existing name include delayed diagnosis, reduced investment into relevant research, and inadequate care, all contributing to enduring stigmas. However, while the organization acknowledges the need for change, they emphasize that simply renaming the disorder does not address the underlying issues.

Concerns About the Renaming Process

PCOS Challenge's Executive Director, Sasha Ottey, articulated that the new name and its adoption should not come at the expense of essential organizational standards. The organization has raised critical points about the evidential basis for the renaming. For example, it was highlighted that the claims used to justify the change have not been sufficiently proven: 1) It remains unclear whether the previous name was indeed responsible for the associated harms; 2) There is no conclusive evidence to support that changing the name will directly improve patient experiences; 3) The potential benefits of PMOS over PCOS have not been adequately established.

Ottey elaborated that altering the terminology will prompt updates across various medical channels, including classification systems and electronic health records. However, these administrative changes do not inherently translate into practical improvements in care practices, available treatments, or research funding. The real work lies in enhancing clinical education, aligning reimbursement models, refining referral systems, and establishing patient-centered care standards.

Voices from the Community

The response from the PCOS community is mixed and complex. It includes excitement about potential recognition and the hope that the new term will lead to a renewed focus on the disorder, alongside apprehension about how this change may introduce further confusion or setbacks. Many in the community feel fatigued and frustrated after years of misdiagnosis and stigma, whereas others are open to the possibilities a new name might bring. All perspectives warrant attention and consideration.

As Ottey noted, “Some are concerned it will cause more harm than the problems it aims to fix.” This sentiment captures the spectrum of emotional responses to such a significant change in nomenclature. Moreover, Ottey emphasizes the necessity for transparency in evaluating the risks associated with renaming, ensuring that adequate assessments are performed before implementing such modifications.

For the Future

In conclusion, the PCOS Challenge insists on upholding the highest standards in medicine as any new approach to addressing PCOS is undertaken. This includes ensuring that the future of care for those affected by this condition is rooted in comprehensive understanding, prompt diagnosis, and holistic treatment plans. The hope remains that the attention brought by this renaming will catalyze meaningful change in the healthcare landscape for people with PCOS, fostering an environment where every patient receives the care, support, and acknowledgment they deserve.

About PCOS Challenge

PCOS Challenge stands as the largest patient advocacy organization globally for those impacted by PCOS, mobilizing efforts to revise health policies at both federal and state levels and prioritizing research that revolves around patient needs.

For more information, contact:
William Patterson
Phone: 404-855-7244
Email: [email protected]